Vera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Purchases 40,607 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) Director Patrick G. Enright bought 40,607 shares of the firm's stock in a transaction dated Tuesday, June 24th. The stock was acquired at an average cost of $22.35 per share, with a total value of $907,566.45. Following the transaction, the director now owns 3,596,593 shares of the company's stock, valued at $80,383,853.55. This trade represents a 1.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Vera Therapeutics Stock Up 3.2%

Shares of Vera Therapeutics stock traded up $0.73 during trading on Wednesday, hitting $23.31. 1,633,416 shares of the stock traded hands, compared to its average volume of 967,187. The company has a fifty day moving average price of $22.51 and a two-hundred day moving average price of $29.28. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $51.61. The company has a quick ratio of 27.68, a current ratio of 27.68 and a debt-to-equity ratio of 0.10.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter in the previous year, the company earned ($0.56) EPS. As a group, research analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on VERA shares. Scotiabank reissued an "outperform" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. HC Wainwright reiterated a "buy" rating and issued a $85.00 target price (up previously from $75.00) on shares of Vera Therapeutics in a report on Monday, June 2nd. Wedbush reduced their price target on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Guggenheim reaffirmed a "buy" rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $65.00.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of VERA. Huntington National Bank acquired a new stake in shares of Vera Therapeutics in the 4th quarter valued at $26,000. AlphaQuest LLC bought a new position in Vera Therapeutics during the fourth quarter valued at about $34,000. GF Fund Management CO. LTD. bought a new position in Vera Therapeutics during the fourth quarter valued at about $56,000. Quarry LP lifted its position in shares of Vera Therapeutics by 25.0% in the first quarter. Quarry LP now owns 2,500 shares of the company's stock worth $60,000 after buying an additional 500 shares during the last quarter. Finally, Summit Investment Advisors Inc. boosted its stake in shares of Vera Therapeutics by 16.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after acquiring an additional 639 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.